pioglitazone has been researched along with Granulocytic Leukemia, Chronic in 7 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When pioglitazone was given temporarily to three CML patients in chronic residual disease in spite of continuous treatment with imatinib, all of them achieved sustained CMR, up to 4." | 1.42 | Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. ( Beressi, JP; Castaigne, S; Chomienne, C; Chrétien, S; Leboulch, P; Maneglier, B; Massonnet, G; Ouzegdouh, Y; Prost, S; Raggueneau, V; Relouzat, F; Rousselot, P; Saliba, J; Spentchian, M; Verhoeyen, E, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Schoepf, AM | 3 |
| Salcher, S | 3 |
| Obexer, P | 3 |
| Gust, R | 3 |
| Pagnano, KBB | 2 |
| Lopes, ABP | 2 |
| Miranda, EC | 1 |
| Delamain, MT | 1 |
| Duarte, GO | 1 |
| Rodrigues, BRV | 1 |
| Povoa, VMO | 2 |
| Furlin, GCP | 1 |
| Vianna, JC | 1 |
| da Silva, MAS | 1 |
| De Souza, CA | 1 |
| De Paula, EV | 2 |
| Delafiori, J | 1 |
| Dias-Audibert, FL | 1 |
| de Oliveira, AN | 1 |
| Catharino, RR | 1 |
| Prost, S | 1 |
| Relouzat, F | 1 |
| Spentchian, M | 1 |
| Ouzegdouh, Y | 1 |
| Saliba, J | 1 |
| Massonnet, G | 1 |
| Beressi, JP | 1 |
| Verhoeyen, E | 1 |
| Raggueneau, V | 1 |
| Maneglier, B | 1 |
| Castaigne, S | 1 |
| Chomienne, C | 1 |
| Chrétien, S | 1 |
| Rousselot, P | 1 |
| Leboulch, P | 1 |
| Brower, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia With Deep Molecular Response - Evaluation of Pioglitazone in Treatment-free Remission (EDI-PIO)[NCT02852486] | Phase 2 | 31 participants (Actual) | Interventional | 2016-06-22 | Active, not recruiting | ||
| Phase 2 Study to Assess the Safety and Efficiency of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Phase Chronic Myelogenous Leukemia Patients[NCT02687425] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pioglitazone and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response.
Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chroni | 2020 |
Metabolic shift of chronic myeloid leukemia patients under imatinib-pioglitazone regimen and discontinuation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Follow-Up St | 2021 |
5 other studies available for pioglitazone and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Proliferation; Cells, Cultured; Chlorocebus aethiop | 2020 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistan | 2020 |
Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Drug D | 2021 |
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Benzam | 2015 |
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Benzam | 2015 |
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Benzam | 2015 |
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Benzam | 2015 |
Pioglitazone with imatinib in CML may reduce residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progress | 2017 |